Pipeline
Our goalsTwo complementary product candidates for colorectal cancer
Pyovita is advancing two complementary preclinical product candidates for colorectal cancer. Both target the protective tumor microenvironment and are based on the same core therapeutic approach, but they use distinct therapeutic formats.
LEAD PROGRAMStandalone therapeutic for colorectal cancer
A novel therapeutic designed to remodel the extracellular matrix surrounding tumors, expose protected cancer cells, and improve access for existing treatments and immune cells.
Development stage: Preclinical
SECOND PROGRAMEngineered bacterial therapy for colorectal cancer
Beneficial bacteria engineered to accumulate within tumors, produce the therapeutic locally, and help remodel the tumor microenvironment. This approach is intended to provide sustained local activity while limiting exposure of healthy tissues.
Development stage: Early preclinical
